MSB 7.69% $1.19 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-434

  1. 7,885 Posts.
    lightbulb Created with Sketch. 624
    Before you bank on an early stop due to overwhelming efficacy on the covid trial at 45% I would look at the posts from @kervio who with his analysis calculated a better chance at the 60% readout
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.